Company Overview
Company Type: Public Company
Website: www.revivethera.com
Number of Employees: 2
Ticker: RVV (CNSX)
Year Founded: 2012


Business Description
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
12.5
EBITDA
(7.9)
Total Enterprise Value
10.1
TEV/EBITDA
NM
EBIT
(7.9)
Cash & ST Invst.
2.7
P/Diluted EPS Before Extra
NM
Net Income
(7.9)
Total Debt
0.2
Price/Tang BV
NM
Total Assets
15.8
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Frank, Michael 
Chairman & CEO
Marrelli, Carmelo 
Chief Financial Officer
McKee, Kelly T.
Chief Scientific Officer Consultant
Mpanju, Onesmo 
Chief Regulatory Affairs Consultant
Welsh, Derrick Alexander
COO of Psilocin Pharma

Key Board Members
Name
Title
Frank, Michael 
Chairman & CEO
Lindzon, Andrew 
Independent Director
Herman, Joshua Jonathan
Independent Director
Jackson, William 
Independent Director
Scovenna, Christian B.
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
The Canadian Venture Building 82 Richmond Street East | Toronto, ON | M5C 1P1 | Canada

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.04
Market Cap (mm)
12.5
Open
 0.04
Shares Out. (mm)
357.6
Previous Close
 0.04
Float %
98.4%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.04/ 0.03
Diluted EPS Excl. Extra Items
(0.02)
52 wk High/Low
 0.34/ 0.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.39
Avg 3M Dly Vlm (mm)
0.41
Beta 5Y
(0.09)


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
CNSX:RVV - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Psilocin Pharma Corp.
Psilocin Pharma Corp. develops production solutions for the active compound psilocybin. Its products include PSY-0.1 -capsules, PSY-0.2 -sublingual spray, PSY-0.3 -gel cap, PSY-0.4/0.5, effervesce tablets, and PSY-0.6 -breath strip. The company was founded in 2020 and is headquartered in Toronto, Canada. As of March 4, 2020, Psilocin Pharma Corp. operates as a subsidiary of Revive Therapeutics Ltd.

United States and Canada
Pharmaceuticals
-
-
-
Herman Holdings Limited (Pending)

United States and Canada
-
-
-
-
Mercury Capital II Limited
As of December 30, 2013, Mercury Capital II Limited was acquired by Revive Therapeutics Ltd., in a reverse merger transaction. Mercury Capital II Limited is a capital pool company. The company was incorporated in 2012 and is based in Toronto, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-30-2022
Jan-12-2023
Private Placement
Target
Revive Therapeutics Ltd. (CNSX:RVV)


3.21
Jan-20-2021
Feb-12-2021
Public Offering
Target
Revive Therapeutics Ltd. (CNSX:RVV)


15.75
Feb-12-2020
Mar-04-2020
Merger/Acquisition
Buyer
Psilocin Pharma Corp.
Revive Therapeutics Ltd. (CNSX:RVV)

2.49
Feb-11-2020
Apr-15-2020
Private Placement
Target
Revive Therapeutics Ltd. (CNSX:RVV)


1.77
Feb-05-2020
Feb-05-2020
Private Placement
Target
Revive Therapeutics Ltd. (CNSX:RVV)


0.16
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-22-2023
Product-Related Announcements
Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development
Jul-28-2023
Product-Related Announcements
Revive Therapeutics Ltd. Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
Jul-06-2023
Product-Related Announcements
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May-30-2023
Product-Related Announcements
Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May-10-2023
Board Meeting
Revive Therapeutics Ltd., Board Meeting, May 10, 2023


Advisors
Most Recent Auditor
Clearhouse LLP
Private Placement Advisors
EMD Financial Inc., Hampton Securities Limited
Public Offering Advisors
Clearhouse LLP, DLA Piper (Canada) LLP, MNP LLP, Peterson & Company


Most Recent Auditor
Clearhouse LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:03 AM
RVV
Revive Therapeutics Ltd 2023_10_05
Reports
14
S&P Global Compustat

Sep 07, 2023 04:01 AM
RVV
Revive Therapeutics Ltd 2023_09_07
Reports
14
S&P Global Compustat

Jul 06, 2023 03:28 AM
RVV
Revive Therapeutics Ltd 2023_07_06
Reports
14
S&P Global Compustat

Jun 01, 2023 04:25 AM
RVV
Revive Therapeutics Ltd 2023_06_01
Reports
14
S&P Global Compustat

May 04, 2023 03:54 AM
RVV
Revive Therapeutics Ltd 2023_05_04
Reports
14
S&P Global Compustat

Apr 06, 2023 04:08 AM
RVV
Revive Therapeutics Ltd 2023_04_06
Reports
14
S&P Global Compustat

Mar 02, 2023 03:46 AM
RVV
Revive Therapeutics Ltd 2023_03_02
Reports
14
S&P Global Compustat

Feb 02, 2023 03:32 AM
RVV
Revive Therapeutics Ltd 2023_02_02
Reports
14
S&P Global Compustat

Jan 05, 2023 03:55 AM
RVV
Revive Therapeutics Ltd 2023_01_05
Reports
14
S&P Global Compustat

Dec 01, 2022 04:05 AM
RVV
Revive Therapeutics Ltd 2022_12_01
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Frank, Michael 

2,066,500

0.58

0.1

Aug-19-2022


Scovenna, Christian B.

2,000,000

0.56

0.1

Aug-19-2022


Jackson, William 

650,000

0.18

0.0

Aug-19-2022


Herman, Joshua Jonathan

625,334

0.17

0.0

Aug-19-2022


Lindzon, Andrew 

205,700

0.06

0.0

Aug-19-2022


MAI Capital Management, LLC

25,000

0.01

0.0

Jun-30-2023


FineMark National Bank & Trust, Asset Management Arm

10,345

0.00

0.0

Jun-30-2023


Cornerstone Planning Group Inc.

10,000

0.00

0.0

Jun-30-2023


Mirae Asset Global Investments Co., Ltd.

0

0.00

0.0

Oct-08-2023


1st Capital Management Group GmbH

0

0.00

0.0

Jun-30-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Mirae Asset Global Investments Co., Ltd.
0
(5,258,858)
1st Capital Management Group GmbH
0
(37,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Bucillamine (Future), Cannabidiol (Future), Cannabinoids (Future), Psilocybin (Future), RELICAN (Future), REV- 003, REV-001 (Future), REV-002 (Future), REV-004 (Future), REV-005 (Future), REV-100 (Future), REV-200 (Future), REV-201 (Future), Tannin-Chitosan Composite Drug Delivery Technology (Future)


Upcoming Events
Date/Time
Type
Oct-27-2023
Estimated Earnings Release Date (S&P Global Derived)
Dec-19-2023
Annual General Meeting
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-05-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
Notice of the Meeting and Record Date
149 KB
Aug-22-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
31 KB
Jul-28-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
25 KB
Jul-06-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
36 KB
May-30-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
32 KB
May-30-2023
Mar-31-2023
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
Interim Financial Statements
173 KB
May-12-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
31 KB
May-02-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
28 KB
Apr-18-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
33 KB
Apr-03-2023
-
Revive Therapeutics Ltd. (CNSX:RVV)
SEDAR
News Releases
78 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Jackson, William  (Independent Director)
Nov-29-2021
Common Shares
150,000
44,743
Derivative Exercise and Retained Stock
30.00
Multiple
Frank, Michael  (Chairman & CEO)
Sep-08-2021
Common Shares
25,000
12,878
Open Market Acquisition
1.22
Multiple
Frank, Michael  (Chairman & CEO)
Sep-07-2021
Common Shares
45,000
21,113
Open Market Acquisition
2.25
Multiple
Lindzon, Andrew  (Independent Director)
Sep-03-2021
Common Shares
52,000
22,545
Open Market Acquisition
33.83
Multiple
Welsh, Derrick Alexander (COO of Psilocin Pharma)
Sep-03-2021
Common Shares
25,000
11,160
Open Market Acquisition
1.19
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Frank, Michael 
Chairman & CEO
4166779277
-
mfrank@mifranconsulting.com
Lindzon, Andrew 
Independent Director
-
-
andrew@ashlin.ca
Herman, Joshua Jonathan
Independent Director
-
-

Jackson, William 
Independent Director
-
-

Scovenna, Christian B.
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Frank, Michael 
Chairman & CEO
4166779277
-
mfrank@mifranconsulting.com
Marrelli, Carmelo 
Chief Financial Officer
(416) 848-0106
-
carm@marrellisupport.ca
McKee, Kelly T.
Chief Scientific Officer Consultant
-
-

Mpanju, Onesmo 
Chief Regulatory Affairs Consultant
-
-

Welsh, Derrick Alexander
COO of Psilocin Pharma
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
